⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720753 | 0.80 | — | — | |
| SCHEMBL14720754 | 0.80 | — | — | |
| SCHEMBL17742617 | 0.78 | — | — | |
| SCHEMBL20606730 | 0.78 | — | — | |
| SCHEMBL20606731 | 0.78 | — | — | |
| SCHEMBL20606728 | 0.78 | — | — | |
| SCHEMBL20606727 | 0.78 | — | — | |
| SCHEMBL20606729 | 0.78 | — | — | |
| SCHEMBL31631820 | 0.76 | — | — | |
| SCHEMBL22528538 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163011-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG | 2013-07-04 | — | — | US | disclosed |